Olsalazine

Evidence Level: L5

Predicted Indications: 10

Olsalazine

Pharmacist Assessment Report

Olsalazine: From an Unspecified Original Indication to Myelodysplastic Syndrome

One-Sentence Summary

Olsalazine is a dimer of 5-aminosalicylic acid (5-ASA) that is registered in Australia as an oral capsule (Dipentum), but the data compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for myelodysplastic syndrome, with a very high model score, but there are 0 clinical trials and 0 publications supporting this prediction. This is a model-only prediction with no clinical evidence behind it.

Quick Overview

Item	Content
Original Indication	Not stated in the data compiled for this report (the ARTG indication text is blank)
Predicted New Indication	Myelodysplastic syndrome
TxGNN Prediction Score	0.9991
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Olsalazine is known to be a dimer of 5-ASA that colonic bacteria cleave into two active molecules. It acts locally in the gut, and systemic exposure to the active moiety is low.

No plausible link between a locally acting colonic anti-inflammatory agent and bone marrow or haematopoietic disease can be established from the data compiled. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Several other top predictions are closely related conditions (myelodysplastic syndrome subtypes, del(5q), and cytopenias or anaemias). They probably reflect the same learned similarities and do not count as independent evidence.

The remaining top-ranked predictions are alopecia-related conditions (alopecia, diffuse alopecia areata, hypotrichosis simplex of the scalp, congenital hypotrichosis milia). For autoimmune hair loss, a speculative anti-inflammatory rationale exists, but minimal systemic absorption limits its relevance, and established therapies have much stronger evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 1728Y	Dipentum	Capsule containing olsalazine sodium 250 mg (oral)	Not stated in the data compiled

Safety Considerations

Drug Interactions: 100 interactions were identified in the interaction screening. The 20 listed in the data compiled include the following.
- Major: human immunoglobulin G (intravenous), human botulinum neurotoxin A/B immune globulin, cidofovir, iothalamic acid.
- Moderate (examples): NSAIDs (ketorolac, ibuprofen, celecoxib, diclofenac), azathioprine, cisplatin, clofarabine, and several nephrotoxic agents (acyclovir, amphotericin B, amikacin, bacitracin, capreomycin, colistimethate).
- Many of these interactions involve potentially nephrotoxic drugs, so renal monitoring is worth considering with co-administration.
Haematological considerations: 5-ASA class drugs carry haematological adverse-event warnings, which argues against benefit in bone marrow disorders. Please confirm the details in the TGA-approved Product Information (PI).

Label warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for these.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a model score. There are no clinical trials or publications, no mechanism of action data, and no plausible biological link between a locally acting colonic agent and myelodysplastic syndrome. The same applies to the other top-ranked predictions (alopecia-related conditions and anaemias).

To proceed, the following is needed:

Mechanism of action data for olsalazine and a defensible mechanistic hypothesis for haematopoietic disease
Preclinical or observational evidence supporting the proposed indication
The approved indication and the safety sections (warnings and contraindications) from the TGA-approved PI
Evidence of adequate systemic exposure at the target site, given the drug’s local colonic action
Review of the haematological safety signal for 5-ASA class drugs in patients with existing cytopenias
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.